Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Cautious Hold Recommendation for Johnson & Johnson Amid ITCI Acquisition Concerns and Market Challenges
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Hold rating on Johnson & Johnson (JNJ – Research Report), with ...
Becker's Spine Review21h
5 medtech notes: Medtronic, Johnson and Johnson and more
From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.
medtechdive1d
J&J coordinating with FDA on US pause of Varipulse due to safety risks
Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...
City, county to vote on health funds for 29th & Grove caught in state bureaucratic struggle
Following the report, several state legislators – including Carr, K.C. Ohaebosim, Henry Helgerson, Susan Estes, Angela ...
Zacks.com on MSN6d
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $147.77, marking a +1.93% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.21%. Elsewhere ...